Recent News
A comprehensive JAMA review synthesizes current evidence on the epidemiology, pathophysiology, clinical evaluation, and treatment of nonspecific low back pain, drawing on 108 publications identified from a PubMed search (2005–2026) and the most recent guidelines from the WHO, ACP, and NICE. While the primary audience is generalists, the review carries important implications for rheumatologists who regularly encounter patients with back pain in the context of inflammatory arthritis, axial spondyloarthritis, and other systemic diseases.Read Article
Redefining axial spondyloarthritis
An editorial in Lancet Rheumatology calls for "..reframing axSpA as a systemic, autoimmune inflammatory disease with multiorgan involvement and substantial unmet need."
The pathogenesis relies on not only HLA-B27, but also on environmental triggers, immune dysregulation, and gut inflammation. AxSpA is not confined to the spine, as gut dysbiosis leads to immune activation, driven by IL-17, IL-22, and TNF.
Read Article
EULAR 2026: Updated Recommendations for Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases
The 2026 EULAR vaccination recommendations, presented by Victoria Furer, were developed by a multinational 25-member task force that include rheumatologists, an https://t.co/AFnsmEYj41
Dr. John Cush @RheumNow ( View Tweet)
Is there a path to precision medicine in #RA? Theres a substantial unmet need. Immunoengineering is possible thru nanotechnological delivery vectors, cellular therapeutics, & biomaterial scaffolds, with compelling preclinical and early clinical support. https://t.co/gL56EOlt7p https://t.co/IFSHOM8g7w
Dr. John Cush @RheumNow ( View Tweet)
Breckenridge Pharmaceutical received FDA approval for their generic version of tofacitinib on 6/4/26. 5 mg and 10 mg tablets are now available in the U.S. market, for both adult and pediatric use. Tofacitinib Tablets are manufactured in Martorelles, Spain. https://t.co/oAh0KQSFgs https://t.co/fNxEm31MAI
Dr. John Cush @RheumNow ( View Tweet)
This is a great WISE read for yound doctors - from the great WISE Dr. Adam Cifu -- Advice for Internship https://t.co/BUtXzJxQxQ
Links:
Dr. John Cush @RheumNow ( View Tweet)
"When you make the choice to avoid becoming the most experienced person in a room (whatever room you’re in), you’re making a bet about the future. " - Seth Godin https://t.co/oWtDNWeoND https://t.co/2dpiFRGaxZ
Links:
Dr. John Cush @RheumNow ( View Tweet)
From Cytokine Endotypes to Clinical Reality in Still’s Disease
Recent EULAR 2026 data highlight a paradigm shift in Still’s disease from syndromic management to biologically informed precision therapy.
https://t.co/fBtkDLPJNE https://t.co/y8NBW6VHHa
Dr. John Cush @RheumNow ( View Tweet)
Genicular artery embolization (GAE) in knee OA? Multiple open label studies & metanalyses suggest a clear pain benefit; BUT 3 sham-controlled RCTs have not demonstrated a statistically significant benefit over placebo. GAE is not addressed by ACR or EULAR guidelines. https://t.co/amIN6kzY74
Dr. John Cush @RheumNow ( View Tweet)
From BiTE to TriTE: Progress of T-cell Engagers in RMDs
At EULAR 2026 in London, T-cell engagers drew attention as a strategy to achieve deep B-cell depletion and drug-free remission in refractory RMDs. BiTEs offer off-the-shelf availability, reversible toxicity from short https://t.co/jjXrf9tcaA
Dr. John Cush @RheumNow ( View Tweet)
How many CAR-T’s do we need to test drive?
There were 93 abstracts with CAR-T in title at #EULAR2026! Additionally, there was an excellent review (WIN) by Dr. Hector Chinoy. We know lots but have more questions.
https://t.co/dGpfffaubX https://t.co/3MS1ZjQExj
Dr. John Cush @RheumNow ( View Tweet)
Single center study of 102 pts starting JAK inhibitor (72% >50yrs; 77% RA) shows only 27.5% received at least one RZV vaccination dose (Shingrix) & only 3 recv RZV within 30 daysof a JAK inhibitor. ????? (I vaccinate everyone going on a JAKi w/ Shingrix - don't you?) https://t.co/7HUqGGBeJ8
Dr. John Cush @RheumNow ( View Tweet)
MTX: SC vs Oral? Metanalysis of 9 RCTs, 974 RA pts. Compared w/ oral, SC MTX signif. incr odds of ACR20 (RR=1.15), ACR50 (RR=1.14) & reduced GI adverse events (RR=0.58), diarrhea (RR=0.42): BUT no difference in ACR70, DAS28-ESR, bioavailability AUC, or other AE https://t.co/54xVnerRuS
Dr. John Cush @RheumNow ( View Tweet)
Do You Zoster Vaccinate? (6.19.2026)
Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.
Read Article
EULAR26 Insights into Gout and Obesity
EurekAlert!
New EULAR 2026 data show continued treat-to-target ULT beats a discontinuation strategy for maintaining gout remission (79.2% vs. 62.9% flare-free), though many who stopped still stayed flare-free. A companion study links gout and rheumatoid arthritis to distinct, adverse body fat patterns tied to higher diabetes and cardiovascular risk.
Read Article
Missed a session at EULAR 2026?
No problem.
The RheumNow Faculty Reporter team was on the ground covering the studies, debates, and breakthroughs that are shaping the future of rheumatology. From JAK safety and CAR-T therapies to advances in lupus, psoriatic arthritis, and ILD, https://t.co/cKmhq8mAIf
Dr. John Cush @RheumNow ( View Tweet)
Late-breaking abstracts presented at EULAR addressed a wide range of clinical concerns and suggested that patients and clinicians have much to look forward to in coming months and years.
https://t.co/m04h8eI3ZM https://t.co/HOQNA5gc6k
Dr. John Cush @RheumNow ( View Tweet)
EULAR 2026 Recommendations on PMR, GCA, and Takayasu Arteritis
On the final day of EULAR, Mukhtyar et al (on behalf of a large international task force) presented the updated EULAR recommendations for management of PMR, GCA, and TAK. There were 5 overarching principles and 12 https://t.co/kpykylEbsr
Dr. John Cush @RheumNow ( View Tweet)
The North American Expert Consensus on ASCVD Screening in Lupus Nephritis
Drs. Sheila Reyes and Shivani Garg discuss abstract OP094, presented in London at the EULAR 2026 Congress
https://t.co/Vm2QFlO3fL https://t.co/4Xp9tkubLh
Dr. John Cush @RheumNow ( View Tweet)
Usual testing for SSA (Ro) pos. in Sjogrens identifies both Ro52 + Ro60 Abs, found in 70% of SjD. Pts who are double pos (Ro52+Ro60) have more severe dz, more Bcell activity. Ro60+ have milder dz; Recent report shows SjD pts have Ro60-specific CD4 T cells, activating Bcells https://t.co/SqoLICHOkS
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
Podcasts
Do You Zoster Vaccinate? (6.19.2026)
RheumNow EULAR 2026 Rheumatology Round Up
EULAR 2026 RA Topic Panel
CAR-T Topic Panel EULAR 2026
Therapeutic Updates
Psoriatic arthritis and overweight or obesity
Sponsored by Lilly Medical Affairs
Dr. Merola presenting the results from TOGETHER‑PsA, a phase 3b trial evaluating the concomitant use of an IL‑17A antagonist and an incretin receptor agonist in adults with psoriatic arthritis and overweight or obesity.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
